List of Skelaxin drug patents
Skelaxin is owned by King Pharms.
Skelaxin contains Metaxalone.
Skelaxin has a total of 1 drug patent out of which 0 drug patents have expired.
Skelaxin was authorised for market use on 30 August, 2002.
Skelaxin is available in tablet;oral dosage forms.
Skelaxin can be used as treatment of musculoskeletal conditions.
The generics of Skelaxin are possible to be released after 06 February, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7122566 | KING PHARMS | Metaxalone products, method of manufacture, and method of use |
Feb, 2026
(2 years from now) | |
Do you want to check out SKELAXIN patents from before 2022?
Drugs and Companies using METAXALONE ingredient
Market Authorisation Date: 30 August, 2002
Treatment: Treatment of musculoskeletal conditions
Dosage: TABLET;ORAL
How can I launch a generic of SKELAXIN before it's patent expiration?
More Information on Dosage
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic